Hyperthermic intraperitoneal chemotherapy procedure for uterine sarcoma following a COVID-19 infection-case report

Abstract

In the current context of the COVID-19 pandemic, major oncologic surgery sometimes had to be postponed for fear of overcrowding the intensive care units, the risk of cross-contamination or the risk of severe morbidity and mortality associated with a perioperative COVID- 19 infection. In this setting, we want to present the first case of a patient who received a hyperthermic intraperitoneal chemotherapy (HIPEC) procedure for uterine sarcoma following a COVID-19 infection. To date, the patient is in good condition and has not developed any postoperative complications.